Back to top
more

Mirati Therapeutics, Inc. (MRTX)

(Delayed Data from NSDQ)

$63.93 USD

63.93
353,481

+2.52 (4.10%)

Updated May 3, 2019 04:00 PM ET

After-Market: $64.05 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Mirati (MRTX) to Begin Clinical Study in MTAP-Deleted Cancers

by Zacks Equity Research

Mirati (MRTX) submits an investigational new drug application to the FDA for MRTX1719 for the treatment of methylthioadenosine phosphoylase-deleted cancers.

Amgen's (AMGN) KRAS Inhibitor Gets CHMP Nod for Lung Cancer

by Zacks Equity Research

The CHMP gives a positive opinion on, and recommends approval to Amgen's (AMGN) KRAS inhibitor, Lumykras for the treatment of advanced non-small-cell lung cancer.

Mirati (MRTX) Beats on Q3 Earnings, Begins NDA Adagrasib Filing

by Zacks Equity Research

Mirati's (MRTX) third-quarter earnings beat estimates. It initiates the NDA submission for adagrasib in second-line NSCLC. Shares rise in after-market trading.

Mirati (MRTX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Mirati (MRTX) delivered earnings and revenue surprises of 45.99% and 91.45%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Mirati (MRTX) Q3 Earnings Expected to Decline

by Zacks Equity Research

Mirati (MRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Lilly's (LLY) Erbitux Gets FDA Nod for Expanded Use in CRC

by Zacks Equity Research

Eli Lilly (LLY) secures FDA approval for Erbitux combined with Pfizer's Braftovi to treat BRAF V600E mutation-positive metastatic CRC in adult patients who received prior therapy.

Onconova (ONTX) KRAS Inhibitor Shows Activity in Lung Cancer

by Zacks Equity Research

Onconova (ONTX) is developing a combination of its rigosertib plus Bristol-Myers' Opdivo for treating cancer with solid tumors. Preliminary data from the phase I/II study demonstrates disease control potential.

Mirati (MRTX) Reports Positive Data From Colorectal Cancer Study

by Zacks Equity Research

Mirati (MRTX) reports positive data from a cohort of the phase I/IIstudy evaluating its KRAS inhibitor adagrasib in patients with KRAS G12C-mutated colorectal cancer.

Mirati (MRTX) Stock Dips on Wider-Than-Expected Q2 Loss

by Zacks Equity Research

Mirati's (MRTX) shares decline after the company's announcement of wider-than-expected loss per share for second-quarter 2021.

    Mirati's (MRTX) Adagrasib Gets Breakthrough Therapy Status

    by Zacks Equity Research

    Mirati (MRTX) is developing adagrasib as a potential treatment for patients suffering from non-small cell lung cancer with KRAS mutation. An NDA is expected to be filed in the second half of 2021.

    Amgen's (AMGN) KRAS Inhibitor Gets FDA Nod for Lung Cancer

    by Zacks Equity Research

    FDA approval of Amgen's (AMGN) Lumakras for KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer is based on positive data from the phase II CodeBreaK 100 study.

    Moving Average Crossover Alert: Mirati Therapeutics (MRTX)

    by Zacks Equity Research

    Mirati Therapeutics (MRTX) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

    Mirati (MRTX) Down 15.7% Since Last Earnings Report: Can It Rebound?

    by Zacks Equity Research

    Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Amgen (AMGN) Files for KRAS Inhibitor for Lung Cancer in Europe

    by Zacks Equity Research

    The regulatory filing for Amgen's (AMGN) sotorasib is based on data from a phase II study, which shows that sotorasib led to durable anticancer activity in advanced NSCLC patients with KRAS G12C mutation.

    Amgen (AMGN) Submits NDA for KRAS Inhibitor for Lung Cancer

    by Zacks Equity Research

    The NDA filing for Amgen's (AMGN) sotorasib is based on data from a phase II study, which showed that sotorasib led to durable anticancer activity in advanced NSCLC patients with KRAS G12C mutation.

    Amgen's (AMGN) KRAS Inhibitor Gets Breakthrough Tag for NSCLC

    by Zacks Equity Research

    The FDA bestows a Breakthrough Therapy status on Amgen's (AMGN) KRAS inhibitor, sotorasib, for treating patients with advanced/metastatic non-small-cell lung cancer with KRAS G12C mutation.

    Why Is Mirati (MRTX) Down 2.2% Since Last Earnings Report?

    by Zacks Equity Research

    Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Mirati (MRTX) Reports Q3 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Mirati (MRTX) delivered earnings and revenue surprises of 3.92% and 1580.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

    Why Mirati Therapeutics (MRTX) Might Surprise This Earnings Season

    by Zacks Equity Research

    Mirati Therapeutics (MRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

    Mirati (MRTX) Expected to Beat Earnings Estimates: Should You Buy?

    by Zacks Equity Research

    Mirati (MRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Mirati (MRTX) Up 6.8% Since Last Earnings Report: Can It Continue?

    by Zacks Equity Research

    Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Analysts Estimate Mirati (MRTX) to Report a Decline in Earnings: What to Look Out for

    by Zacks Equity Research

    Mirati (MRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Mirati (MRTX) Up 4.1% Since Last Earnings Report: Can It Continue?

    by Zacks Equity Research

    Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Mirati (MRTX) Reports Q1 Loss, Lags Revenue Estimates

    by Zacks Equity Research

    Mirati (MRTX) delivered earnings and revenue surprises of -22.42% and -58.92%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

    Analysts Estimate Mirati (MRTX) to Report a Decline in Earnings: What to Look Out for

    by Zacks Equity Research

    Mirati (MRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.